Hepatitis B（B型肝炎 ）
What is Hepatitis B
Hepatitis B is a viral
infection that is spread through contact with blood. In the U.S., hepatitis B
is primarily a disease of adults and is spread through sexual contact or shared
needles used with illicit drugs. Hepatitis B is more common in the general
population in East and Southeast Asia and in Sub-Saharan Africa. Even in these
areas, the risk for contracting the infection is exceptionally low unless blood
products or close intimate contact is anticipated. If you contract hepatitis B,
you can become very ill for a few weeks or a few months but the risk of
long-term complication is much less than generally believed. More than 95% of
those who contract hepatitis B fully recover, resulting in lifetime immunity. Unless
you plan to spend extended periods in close contact with infected persons, the
risk of contracting hepatitis B while traveling is negligible. (Dr. Sherri Tenpenny, 2008)
Hepatitis B is Rare
According to Guide to Clinical Preventive Services, in the U.S. "the greatest reported incidence [of hepatitis B] occurs in adults aged 20-39" and "the number of cases peaked in 1985 and has shown a continuous gradual decline since that time." According to Harrison'sPrinciples of Internal Medicine (1994), mother to child transmission of hepatitis B "is uncommon in North America and western Europe."
The U.S. and western Europe have always had among the lowest rates of hepatitis B disease in the world (0.1% to 0.5% of the general population). In 1991, there were 18,003 cases of hepatitis B reported in the U.S. out of a total U.S. population of 248 million.
According to Guide to Clinical Preventive Services, in the U.S. "the greatest reported incidence [of hepatitis B] occurs in adults aged 20-39" and "the number of cases peaked in 1985 and has shown a continuous gradual decline since that time." According to Harrison'sPrinciples of Internal Medicine (1994), mother to child transmission of hepatitis B "is uncommon in North America and western Europe."
The U.S. and western Europe have always had among the lowest rates of hepatitis B disease in the world (0.1% to 0.5% of the general population). In 1991, there were 18,003 cases of hepatitis B reported in the U.S. out of a total U.S. population of 248 million.
Hepatitis B is Benign For Most
According to Harrison's, in cases of acute hepatitis B "most patients do not require hospital care" and "95 percent of patients have a favorable course and recover completely" with the case-fatality ratio being "very low (approximately 0.1 percent)."
Hepatitis B is Not Highly Contagious
Hepatitis B is primarily an adult disease transmitted through infected body fluids in high risk populations such as needle using drug addicts; sexually promiscuous heterosexual and homosexual adults. To inoculate small children with this vaccine is extremely inappropriate.
According to Harrison's, in cases of acute hepatitis B "most patients do not require hospital care" and "95 percent of patients have a favorable course and recover completely" with the case-fatality ratio being "very low (approximately 0.1 percent)."
Hepatitis B is Not Highly Contagious
Hepatitis B is primarily an adult disease transmitted through infected body fluids in high risk populations such as needle using drug addicts; sexually promiscuous heterosexual and homosexual adults. To inoculate small children with this vaccine is extremely inappropriate.
The Wrong People
According to CDC Prevention Guidelines: A Guide to Action (1997), a book written by federal public health officials at the U.S. government Centers for Disease Control (CDC), "the sources of [hepatitis B] infection for most cases include intravenous drug use (28%), heterosexual contact with infected persons or multiple partners (22%) and homosexual activity (9%)."
According to CDC Prevention Guidelines: A Guide to Action (1997), a book written by federal public health officials at the U.S. government Centers for Disease Control (CDC), "the sources of [hepatitis B] infection for most cases include intravenous drug use (28%), heterosexual contact with infected persons or multiple partners (22%) and homosexual activity (9%)."
From NVIC (http://909shot.com/Diseases/hepbnlr.htm)
Hepatitis B Vaccine Licensed By FDA Without Adequate Proof of Long
Term Safety
In 1986, the FDA gave Merck & Co. a license to market the first recombinant DNA hepatitis B vaccine, which replaced the old hepatitis B vaccines made from blood taken from human chronic hepatitis B virus carriers. In awarding Merck & Co. and, later, SmithKline BeechamPharmaceuticals, licenses to market their genetically engineered hepatitis B vaccines in the U.S., the FDA allowed both drug companies to use "safety" studies which only included a few thousand children monitored for only four or five days after vaccination to check for reactions. As "proof" their hepatitis B vaccine is safe to be used in children, Merck & Co. stated in their 1993 product insert that "In a group of studies, 1636 doses of RECOMBIVAX HB were administered to 653 healthy infants and children (up to 10 years of age) who were monitored for 5 days after each dose."
In 1986, the FDA gave Merck & Co. a license to market the first recombinant DNA hepatitis B vaccine, which replaced the old hepatitis B vaccines made from blood taken from human chronic hepatitis B virus carriers. In awarding Merck & Co. and, later, SmithKline BeechamPharmaceuticals, licenses to market their genetically engineered hepatitis B vaccines in the U.S., the FDA allowed both drug companies to use "safety" studies which only included a few thousand children monitored for only four or five days after vaccination to check for reactions. As "proof" their hepatitis B vaccine is safe to be used in children, Merck & Co. stated in their 1993 product insert that "In a group of studies, 1636 doses of RECOMBIVAX HB were administered to 653 healthy infants and children (up to 10 years of age) who were monitored for 5 days after each dose."
Hepatitis Vaccines Cause Autoimmune and Demyelinating Diseases
Montinari et al published a study in Italy evaluating 30 children and adults, the majority aged 3 to 9 months, who suffered central nervous system disorders, such as seizures and autism, following hepatitis B vaccination. The purpose of the study was to investigate whether there is an immunogenetic basis (autoimmune type) responsible for the demyelination process in the brain that can occur following recombinant hepatitis B vaccination. The authors concluded "autoimmune diseases are more frequent in nations where vaccines are widely used, the so called "clear" communities" and they identified several potential genetic markers that "may visualize risk patients for autoimmune diseases following hepatitis B vaccination.
Montinari et al published a study in Italy evaluating 30 children and adults, the majority aged 3 to 9 months, who suffered central nervous system disorders, such as seizures and autism, following hepatitis B vaccination. The purpose of the study was to investigate whether there is an immunogenetic basis (autoimmune type) responsible for the demyelination process in the brain that can occur following recombinant hepatitis B vaccination. The authors concluded "autoimmune diseases are more frequent in nations where vaccines are widely used, the so called "clear" communities" and they identified several potential genetic markers that "may visualize risk patients for autoimmune diseases following hepatitis B vaccination.
In 1996, Burton A. Waisbren, M.D., a cell biologist and infectious
disease specialist, who is a founding member of the Infectious Disease Society
of America and past President of the Infectious Disease Society of Milwaukee,
pointed out in the Wisconsin Medical Journal that "there is an increasing
number of reports in the refereed medical literature about demyelinizing
diseases occurring after an individual has received the hepatitis B
vaccination...since the hepatitis B virus itself has been reported to cause
autoimmune problems, should we not be wary of giving antigens that seem to have
triggered these problems?" Waisbren, in a presentation before a 1996
Institute of Medicine Vaccine Safety Forum, warned that genetically engineered
hepatitis B vaccines contain polypeptide sequences that are present in human
neurologic tissues such as myelin and that, by a mechanism called molecular
mimicry, these polypeptides can act as autoantigens which can induce autoimmune
demyelinating diseases of the brain such as multiple sclerosis.
(From NVIC (http://909shot.com/Diseases/hepbnlr.htm)
Documentations of the
risk, see http://www.novaccine.com/vaccine-risks/index.asp?sv_id=46
Other than sources from World Association for Vaccine Education, there
are some other disorders related to Hepatitis B mentioned in <Saying No to
Vaccines> by Dr. Sherri Tenpenny as follow:
Autoimmune Reactions
Arthritis Reactions
Deafness Citations
Neurological Reactions
Renal (kidney)
Reactions
Skin Reactions
Vascular (blood)
Reactions
There are so many
documentations stated by Dr. Sherri Tenpenny, please refer to <Saying No to
Vaccines> for further information.
What are the reactions and conditions?
Reactions and Conditions
|
(Sources: World Association for Vaccine Education,
http://www.novaccine.com/reactions-conditions/)
What are the ingredients in Hepatitis B Vaccine?
(Vaccine availability,
ingredients and manufacturers change frequently. Correct as of November 2007)
Energix-B
Inactivated Hepatitis
B Vaccine
GlaxoSmithKlein (GSK)
COMMENT:
Adult=20mcg/cc injection is twice the dose of Recombivax; Pediatric=10mcg/0.5cc
injection
Contents: Aluminium
hydroxide, Disodium phosphate, sodium dihydrogen phosphate, yeast protein
(50mg), trace thimerosal (please refer
to “Vaccine Ingredients”)
Recombivax
Hepatitis B Vaccine
Merck
Adult 10mcg/cc
injection; Pediatric 5mcg/cc injection
Contents: Hepatitis B
surface antigen (HBsAg), aluminium hydroxide, recombined with Saccharomyces
cerevisiae yeast (10mg/cc), soy peptone, dextrose, amino acids, phosphate
buffer, formaldehyde, potassium aluminium sulfate
(From Dr. Sherri
Tenpenny <Saying No to Vaccines>)
For more information,
see http://www.novaccine.com/specific-vaccines/vaccine.asp?v_id=46
No comments:
Post a Comment